SRC
NVO

Sage Rhino Capital’s Novo Nordisk NVO Stock Holding History

Sage Rhino Capital’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$534K Buy
11,148
+2,448
+28% +$105K 0.09% 148
2026
Q1 		$320K Sell
8,700
-1,769
-17% -$83.8K 0.06% 185
2025
Q4 		$533K Sell
10,469
-704
-6% -$36K 0.1% 141
2025
Q3 		$620K Sell
11,173
-459
-4% -$26.9K 0.12% 129
2025
Q2 		$803K Sell
11,632
-185
-2% -$12.6K 0.17% 103
2025
Q1 		$821K Sell
11,817
-274
-2% -$22.6K 0.19% 97
2024
Q4 		$1.04M Sell
12,091
-294
-2% -$31.8K 0.23% 85
2024
Q3 		$1.47M Buy
12,385
+55
+0.4% +$7.33K 0.33% 61
2024
Q2 		$1.76M Buy
12,330
+10
+0.1% +$1.32K 0.42% 54
2024
Q1 		$1.58M Buy
12,320
+89
+0.7% +$10.6K 0.37% 58
2023
Q4 		$1.27M Buy
12,231
+71
+0.6% +$7.02K 0.32% 62
2023
Q3 		$1.11M Buy
12,160
+160
+1% +$14.1K 0.31% 67
2023
Q2 		$971K Sell
12,000
-294
-2% -$24K 0.27% 74
2023
Q1 		$978K Buy
12,294
+204
+2% +$14.5K 0.29% 69
2022
Q4 		$818K Buy
12,090
+394
+3% +$23.1K 0.26% 75
2022
Q3 		$583K Sell
11,696
-294
-2% -$15.8K 0.23% 79
2022
Q2 		$668K Buy
11,990
+234
+2% +$13K 0.26% 73
2022
Q1 		$653K Buy
11,756
+512
+5% +$26.3K 0.2% 94
2021
Q4 		$630K Buy
11,244
+1,150
+11% +$62.3K 0.18% 102
2021
Q3 		$485K Buy
10,094
+312
+3% +$15.1K 0.15% 110
2021
Q2 		$410K Buy
9,782
+460
+5% +$17.8K 0.12% 130
2021
Q1 		$314K Buy
9,322
+444
+5% +$15.8K 0.1% 134
2020
Q4 		$310K Buy
8,878
+14
+0.2% +$484 0.12% 124
2020
Q3 		$308K Sell
8,864
-12
-0.1% -$400 0.15% 112
2020
Q2 		$291K Buy
8,876
+226
+3% +$7.21K 0.15% 114
2020
Q1 		$260K Buy
8,650
+770
+10% +$22.9K 0.19% 99
2019
Q4 		$231K Buy
7,880
+104
+1% +$2.88K 0.13% 131
2019
Q3 		$201K Sell
7,776
-120
-2% -$3.03K 0.13% 133
2019
Q2 		$202K Buy
+7,896
New +$195K 0.13% 124

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Sage Rhino Capital's NVO Position: Q2 2026 in Review

Sage Rhino Capital increased its Novo Nordisk (NVO) stake by 28% in Q2 2026, buying an estimated $105K and bringing the position to 11,148 shares worth $534K. The position accounts for 0.09% of the portfolio, ranked #148.

Sage Rhino Capital first reported a position in NVO in Q2 2019 and has held it in 29 quarters since. The position peaked at $1.76M in Q2 2024. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Sage Rhino Capital held 11,148 shares of Novo Nordisk worth $534K as of Q2 2026.
  • Sage Rhino Capital bought 2,448 Novo Nordisk shares in Q2 2026, an estimated $105K.
  • Novo Nordisk made up 0.09% of Sage Rhino Capital's portfolio in Q2 2026, its #148 holding.
  • Sage Rhino Capital first reported a position in Novo Nordisk in Q2 2019 and has held it in 29 quarters since.
  • Sage Rhino Capital's Novo Nordisk position peaked at $1.76M in Q2 2024.
  • 1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Sage Rhino Capital's 13F filing for Q2 2026, filed 3 Aug 2026.